Biodeal Pharmaceuticals has acquired a sterile injectable manufacturing facility in Paonta Sahib, Himachal Pradesh from Biological E. The acquisition marks a strategic expansion of Biodeal's manufacturing platform into sterile injectables for global markets, adding established regulatory credentials, specialised capabilities and significant manufacturing capacity to its portfolio.

The facility is equipped for general injectables and Carbapenem manufacturing in vial formats, supported by German-made Groninger processing lines, with current annual capacity of around 135 million units. There is scope to expand to the facility's full capacity of 17 production lines and to add Pre-Filled Syringe (PFS) and lyophilised formats.

Biodeal is pursuing PIC/S and EU accreditation for the facility as part of its plans to expand into additional regulated markets.

Spread across a 14-acre campus, the Paonta Sahib facility comprises approximately 39,000 square meters of built-up manufacturing space and has the potential to add a further capacity of 30 million units through near-term expansion.

Located approximately 50 kilometers from Biodeal’s existing Nalagarh facility, the acquisition also strengthens the company’s manufacturing footprint within Himachal Pradesh’s established pharmaceutical corridor.

Anurag Kumar, Chairman and Managing Director, Biodeal Pharmaceuticals, said, "This acquisition is a deliberate step, not an opportunistic one. RMB Capitalworks backed our growth path with conviction, and Paonta Sahib gives us a regulated-market manufacturing base with credentials and capabilities that normally take years to build. It changes the category of company Biodeal competes in and puts us in a strong position to continue building a durable, high-value regulated-market business."

With this acquisition, Biodeal adds established manufacturing capacity and credentials to its platform, broadening the range of complex injectable manufacturing it can offer pharmaceutical customers globally—spanning Carbapenems for serious bacterial and drug-resistant infections, and in process of expanding into ready-to-use pre-filled syringe formats, and lyophilised products with extended stability and shelf life.

Mahima Datla, Managing Director, Biological E, said, "As Biological E continues to focus our investment on our new vaccine R&D and CDMO campus in Telangana, divesting our Paonta Sahib facility to a capable, growth-oriented partner was a natural next step. We are confident Biodeal Pharmaceuticals is well positioned to build on the strong foundation established at this facility, and we wish them continued success as they take it forward.”